# Innovative Solutions & Support Inc: financial statements, quarterly

IA · Nasdaq · CIK 836690 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/ia.md) · [Financials](/companies/ia/financials.md) · [Filings](/companies/ia/filings.md) · [Insiders](/companies/ia/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ia/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.0 d](/filings/0001104659-25-123847.md) | [9.3](/filings/0001558370-25-001027.md) | [10.7](/filings/0001558370-25-007895.md) | [11.8](/filings/0001558370-25-011532.md) | [15.4 d](/filings/0001104659-25-123847.md) | [16.0](/filings/0001104659-26-015306.md) | [21.9](/filings/0001104659-26-062716.md) | [24.1](/filings/0001104659-26-095962.md) | [22.2 d](/filings/0001104659-25-123847.md) | [21.8](/filings/0001104659-26-015306.md) | [22.4](/filings/0001104659-26-062716.md) | [26.7](/filings/0001104659-26-095962.md) |
| Cost of revenue | $m | [4.9 d](/filings/0001104659-25-123847.md) | [3.8](/filings/0001558370-25-001027.md) | [5.2](/filings/0001558370-25-007895.md) | [5.5](/filings/0001558370-25-011532.md) | [6.9 d](/filings/0001104659-25-123847.md) | [9.4](/filings/0001104659-26-015306.md) | [10.7](/filings/0001104659-26-062716.md) | [15.6](/filings/0001104659-26-095962.md) | [8.2 d](/filings/0001104659-25-123847.md) | [9.9](/filings/0001104659-26-015306.md) | [10.9](/filings/0001104659-26-062716.md) | [12.9](/filings/0001104659-26-095962.md) |
| Gross profit | $m | [8.1 d](/filings/0001104659-25-123847.md) | [5.5](/filings/0001558370-25-001027.md) | [5.6](/filings/0001558370-25-007895.md) | [6.3](/filings/0001558370-25-011532.md) | [8.5 d](/filings/0001104659-25-123847.md) | [6.6](/filings/0001104659-26-015306.md) | [11.3](/filings/0001104659-26-062716.md) | [8.6](/filings/0001104659-26-095962.md) | [14.1 d](/filings/0001104659-25-123847.md) | [11.9](/filings/0001104659-26-015306.md) | [11.4](/filings/0001104659-26-062716.md) | [13.8](/filings/0001104659-26-095962.md) |
| Research and development | $m | [0.7 d](/filings/0001104659-25-123847.md) | [0.9](/filings/0001558370-25-001027.md) | [1.0](/filings/0001558370-25-007895.md) | [1.1](/filings/0001558370-25-011532.md) | [1.1 d](/filings/0001104659-25-123847.md) | [1.1](/filings/0001104659-26-015306.md) | [0.9](/filings/0001104659-26-062716.md) | [0.9](/filings/0001104659-26-095962.md) | [1.1 d](/filings/0001104659-25-123847.md) | [1.3](/filings/0001104659-26-015306.md) | [1.8](/filings/0001104659-26-062716.md) | [1.9](/filings/0001104659-26-095962.md) |
| Selling, general and administrative | $m | [3.7 d](/filings/0001104659-25-123847.md) | [3.0](/filings/0001558370-25-001027.md) | [2.9](/filings/0001558370-25-007895.md) | [3.1](/filings/0001558370-25-011532.md) | [3.1 d](/filings/0001104659-25-123847.md) | [4.2](/filings/0001104659-26-015306.md) | [3.4](/filings/0001104659-26-062716.md) | [4.2](/filings/0001104659-26-095962.md) | [4.7 d](/filings/0001104659-25-123847.md) | [4.3](/filings/0001104659-26-015306.md) | [4.7](/filings/0001104659-26-062716.md) | [5.9](/filings/0001104659-26-095962.md) |
| Operating income | $m | [3.7 d](/filings/0001104659-25-123847.md) | [1.6](/filings/0001558370-25-001027.md) | [1.6](/filings/0001558370-25-007895.md) | [2.0](/filings/0001558370-25-011532.md) | [4.4 d](/filings/0001104659-25-123847.md) | [1.3](/filings/0001104659-26-015306.md) | [7.0](/filings/0001104659-26-062716.md) | [3.5](/filings/0001104659-26-095962.md) | [8.2 d](/filings/0001104659-25-123847.md) | [6.3](/filings/0001104659-26-015306.md) | [4.9](/filings/0001104659-26-062716.md) | [6.0](/filings/0001104659-26-095962.md) |
| Interest expense | $m | not reported | [0.4](/filings/0001558370-25-001027.md) | [0.2](/filings/0001558370-25-007895.md) | [0.2](/filings/0001558370-25-011532.md) | [0.2 d](/filings/0001104659-25-123847.md) | [0.4](/filings/0001104659-26-015306.md) | [0.4](/filings/0001104659-26-062716.md) | [0.4](/filings/0001104659-26-095962.md) | [0.5 d](/filings/0001104659-25-123847.md) | [0.5](/filings/0001104659-26-015306.md) | [0.5](/filings/0001104659-26-062716.md) | [1.0](/filings/0001104659-26-095962.md) |
| Income tax | $m | [0.7 d](/filings/0001104659-25-123847.md) | [0.3](/filings/0001558370-25-001027.md) | [0.3](/filings/0001558370-25-007895.md) | [0.3](/filings/0001558370-25-011532.md) | [0.9 d](/filings/0001104659-25-123847.md) | [0.2](/filings/0001104659-26-015306.md) | [1.3](/filings/0001104659-26-062716.md) | [0.7](/filings/0001104659-26-095962.md) | [2.2 d](/filings/0001104659-25-123847.md) | [1.8](/filings/0001104659-26-015306.md) | [1.0](/filings/0001104659-26-062716.md) | [0.5](/filings/0001104659-26-095962.md) |
| Net income | $m | [2.6 d](/filings/0001104659-25-123847.md) | [1.1](/filings/0001558370-25-011532.md) | [1.2](/filings/0001558370-25-011532.md) | [1.6](/filings/0001558370-25-011532.md) | [3.2 d](/filings/0001104659-25-123847.md) | [0.7](/filings/0001104659-26-095962.md) | [5.3](/filings/0001104659-26-095962.md) | [2.4](/filings/0001104659-26-095962.md) | [7.1 d](/filings/0001104659-25-123847.md) | [4.1](/filings/0001104659-26-095962.md) | [3.4](/filings/0001104659-26-095962.md) | [4.5](/filings/0001104659-26-095962.md) |
| Diluted EPS | $ per share | not reported | [0.06](/filings/0001558370-25-001027.md) | [0.07](/filings/0001558370-25-007895.md) | [0.09](/filings/0001558370-25-011532.md) | not reported | [0.04](/filings/0001104659-26-015306.md) | [0.30](/filings/0001104659-26-062716.md) | [0.14](/filings/0001104659-26-095962.md) | not reported | [0.22](/filings/0001104659-26-015306.md) | [0.19](/filings/0001104659-26-062716.md) | [0.25](/filings/0001104659-26-095962.md) |
| Basic EPS | $ per share | not reported | [0.06](/filings/0001558370-25-001027.md) | [0.07](/filings/0001558370-25-007895.md) | [0.09](/filings/0001558370-25-011532.md) | not reported | [0.04](/filings/0001104659-26-015306.md) | [0.30](/filings/0001104659-26-062716.md) | [0.14](/filings/0001104659-26-095962.md) | not reported | [0.23](/filings/0001104659-26-015306.md) | [0.19](/filings/0001104659-26-062716.md) | [0.25](/filings/0001104659-26-095962.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.1](/filings/0001558370-24-016501.md) | [0.5](/filings/0001558370-24-001167.md) | [0.6](/filings/0001558370-24-008148.md) | [0.5](/filings/0001558370-24-012215.md) | [0.5](/filings/0001104659-25-123847.md) | [0.6](/filings/0001558370-25-001027.md) | [1.2](/filings/0001558370-25-007895.md) | [0.6](/filings/0001558370-25-011532.md) | [2.7](/filings/0001104659-26-095962.md) | [8.3](/filings/0001104659-26-015306.md) | [6.8](/filings/0001104659-26-062716.md) | [10.7](/filings/0001104659-26-095962.md) |
| Current assets | $m | [34.7](/filings/0001558370-24-016501.md) | [26.9](/filings/0001558370-24-001167.md) | [24.5](/filings/0001558370-24-008148.md) | [26.4](/filings/0001558370-24-012215.md) | [34.7](/filings/0001104659-25-123847.md) | [34.1](/filings/0001558370-25-001027.md) | [41.5](/filings/0001558370-25-007895.md) | [39.8](/filings/0001558370-25-011532.md) | [50.7](/filings/0001104659-26-095962.md) | [58.4](/filings/0001104659-26-015306.md) | [53.2](/filings/0001104659-26-062716.md) | [64.4](/filings/0001104659-26-095962.md) |
| Total assets | $m | [63.0](/filings/0001558370-24-016501.md) | [55.7](/filings/0001558370-24-001167.md) | [57.6](/filings/0001558370-24-008148.md) | [59.8](/filings/0001558370-24-012215.md) | [82.4](/filings/0001104659-25-123847.md) | [81.3](/filings/0001558370-25-001027.md) | [89.9](/filings/0001558370-25-007895.md) | [91.8](/filings/0001558370-25-011532.md) | [103](/filings/0001104659-26-095962.md) | [110](/filings/0001104659-26-015306.md) | [138](/filings/0001104659-26-062716.md) | [148](/filings/0001104659-26-095962.md) |
| Current liabilities | $m | [6.4](/filings/0001558370-24-016501.md) | [15.4](/filings/0001558370-24-001167.md) | [15.8](/filings/0001558370-24-008148.md) | [16.2](/filings/0001558370-24-012215.md) | [7.3](/filings/0001104659-25-123847.md) | [6.5](/filings/0001558370-25-001027.md) | [8.5](/filings/0001558370-25-007895.md) | [11.3](/filings/0001558370-25-011532.md) | [16.7](/filings/0001104659-26-095962.md) | [19.7](/filings/0001104659-26-015306.md) | [16.5](/filings/0001104659-26-062716.md) | [21.7](/filings/0001104659-26-095962.md) |
| Total liabilities | $m | [24.3](/filings/0001558370-24-016501.md) | [15.8](/filings/0001558370-24-001167.md) | [16.2](/filings/0001558370-24-008148.md) | [16.6](/filings/0001558370-24-012215.md) | [35.7](/filings/0001104659-25-123847.md) | [33.5](/filings/0001558370-25-001027.md) | [36.4](/filings/0001558370-25-007895.md) | [35.0](/filings/0001558370-25-011532.md) | [38.8](/filings/0001104659-26-095962.md) | [41.2](/filings/0001104659-26-015306.md) | [66.2](/filings/0001104659-26-062716.md) | [70.8](/filings/0001104659-26-095962.md) |
| Long-term debt | $m | [17.5](/filings/0001558370-24-016501.md) | not reported | not reported | not reported | [28.0](/filings/0001104659-25-123847.md) | [26.5](/filings/0001558370-25-001027.md) | [27.4](/filings/0001558370-25-007895.md) | [23.3](/filings/0001558370-25-011532.md) | [21.7](/filings/0001104659-26-095962.md) | [21.1](/filings/0001104659-26-015306.md) | [49.3](/filings/0001104659-26-062716.md) | [48.7](/filings/0001104659-26-095962.md) |
| Current portion of debt | $m | [2.0](/filings/0001558370-24-016501.md) | [10.6](/filings/0001558370-24-001167.md) | [10.6](/filings/0001558370-24-008148.md) | [9.9](/filings/0001558370-24-012215.md) | not reported | not reported | not reported | not reported | [2.4](/filings/0001104659-26-095962.md) | [2.4](/filings/0001104659-26-015306.md) | [5.6](/filings/0001104659-26-062716.md) | [5.6](/filings/0001104659-26-095962.md) |
| Shareholders' equity | $m | [38.6](/filings/0001104659-25-123847.md) | [39.9](/filings/0001558370-25-011532.md) | [41.4](/filings/0001558370-25-011532.md) | [43.2](/filings/0001558370-25-011532.md) | [46.6](/filings/0001104659-26-095962.md) | [47.8](/filings/0001104659-26-095962.md) | [53.5](/filings/0001104659-26-095962.md) | [56.8](/filings/0001104659-26-095962.md) | [64.6](/filings/0001104659-26-095962.md) | [68.7](/filings/0001104659-26-095962.md) | [72.1](/filings/0001104659-26-095962.md) | [77.2](/filings/0001104659-26-095962.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,158 d](/filings/0001104659-25-123847.md) | [4,216](/filings/0001558370-25-001027.md) | [201 d](/filings/0001558370-25-007895.md) | [934 d](/filings/0001558370-25-011532.md) | [445 d](/filings/0001104659-25-123847.md) | [1,841](/filings/0001104659-26-015306.md) | [1,288 d](/filings/0001104659-26-062716.md) | [7,207 d](/filings/0001104659-26-095962.md) | [2,967 d](/filings/0001104659-25-123847.md) | [8,160](/filings/0001104659-26-015306.md) | [2,291 d](/filings/0001104659-26-062716.md) | [5,090 d](/filings/0001104659-26-095962.md) |
| Capital expenditure | $k | [133 d](/filings/0001104659-25-123847.md) | [183](/filings/0001558370-25-001027.md) | [126 d](/filings/0001558370-25-007895.md) | [203 d](/filings/0001558370-25-011532.md) | [146 d](/filings/0001104659-25-123847.md) | [261](/filings/0001104659-26-015306.md) | [1,556 d](/filings/0001104659-26-062716.md) | [3,688 d](/filings/0001104659-26-095962.md) | [1,007 d](/filings/0001104659-25-123847.md) | [1,110](/filings/0001104659-26-015306.md) | [1,625 d](/filings/0001104659-26-062716.md) | [476 d](/filings/0001104659-26-095962.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.3](/filings/0001558370-24-001167.md) | [17.4](/filings/0001558370-24-008148.md) | [17.6](/filings/0001558370-24-012215.md) | [17.5](/filings/0001558370-25-001027.md) | [17.5](/filings/0001558370-25-007895.md) | [17.5](/filings/0001558370-25-011532.md) | [17.6](/filings/0001104659-26-015306.md) | [17.6](/filings/0001104659-26-062716.md) | [17.8](/filings/0001104659-26-095962.md) | [18.1](/filings/0001104659-26-015306.md) | [18.3](/filings/0001104659-26-062716.md) | [18.3](/filings/0001104659-26-095962.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,899,173 at 2026-07-31, from the cover of the [10-Q filed 2026-08-13](/filings/0001104659-26-095962.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.